Gunsynd
GUN · AIM · Health Care · mcap £1.7m · 0.1p 2 open situations →
- EV
- £1.5m
- EV / EBIT
- –
- Net cash
- £563k
- FCF yield
- -32.1%
- Revenue
- –
- Share price 1y
- −21%
- Insiders 12m
- bought £25k
- Next report
- around 25 Nov
Open · 2
An activist campaign
Led to Eagle Gold Project farm-in – Circular published; approval pending; requisition received
On 16 October 2026 Gunsynd confirmed receipt of a notice purporting to requisition a general meeting under section 312 of the Companies Act 2006, after share price movement and bulletin-board commentary. The Board is assessing validity with legal advisers and has not named the requisitioner or the resolutions. It comes days after the conversion-to-explorer circular.
- Notice
- Purported requisition of a general meeting under s.312 Companies Act 2006, received 2026-10-16
- Requisitioner
- Not named by the company; details were posted on an internet bulletin board by an individual
- Board response
- Assessing validity with legal advisers; will respond in due course
- Resolutions
- Not stated
Next: Board assesses validity and responds to the requisitioning party
- 16 Oct 2026 campaign
Eagle Gold Project farm-in
Follows from An activist campaign – campaign
On 12 October 2026 the Board published a circular proposing to drop AIM investing-company status, become an operating exploration company focused on the wholly-owned Barb gold project, and consolidate shares 12 for 1. Shareholder approval is pending. A requisition notice for a general meeting, received 16 October, adds uncertainty; its content and any link to the plan are not stated.
- Plan
- Convert to operating exploration company with wholly-owned flagship Barb gold project
- Capital reorganisation
- 12 for 1 consolidation, about 134.6m new shares from 1,615,598,332
- Status
- Shareholder approval pending
- New risk
- Requisition notice received 2026-10-16; link to the plan not stated
Next: Board response to the requisition; shareholder vote on the conversion
- 16 Oct 2026 Circular published; approval pending; requisition received
- 12 Oct 2026 Circular published; shareholder approval pending
- 26 Mar 2026 10% purchase agreed; Medcaw buying other 90% at premium
- 19 Nov 2025 Binding term sheet signed; agreement pending
Closed · 2
Company filings. Not investment advice.